This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/2/2026
Good day and welcome to the Vertex Pharmaceuticals third quarter 2026 earnings call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on your touchtone phone. And to withdraw your question, please press star then 2. Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead.
Good evening, all. My name is Susie Lisa, and as the Senior Vice President of Investor Relations, it is my pleasure to welcome you to our third quarter 2026 Financial Results Conference call. On tonight's call, making prepared remarks, we have Dr. Reshma Kewalramani, Vertex's CEO and President, Charlie Wagner, Chief Operating Officer and Chief Financial Officer, and Duncan McKechnie, Chief Commercial Officer. Given the January 1 transition by Charlie to the COO role solely, please note that this is his last quarterly earnings call and his successor, Jonathan Poole, our current SVP of Finance, will join us for our Q4 2026 call in February. We recommend that you access the webcast slides as you listen to this call. The call is being recorded and a replay will be available on our website. We will make forward-looking statements on this call that are subject to the risks and uncertainties discussed in detail in today's press release and in our filings with the Securities and Exchange Commission. These statements, including without limitation those regarding Vertex's marketed medicines for cystic fibrosis, Sickle Cell Disease, Beta Thalassemia, Moderate to Severe Acute Pain, and Acromegaly, Our Pipeline, the recently completed acquisition of Krenetics Pharmaceuticals and the expected benefits of that transaction, and Vertex's future financial performance are based on management's current assumptions. Actual outcomes and events could differ materially. I would also note that select financial results and guidance that we will review on the call this evening are presented on a non-GAAP basis. I'll now turn the call over to Reshma.
Thanks Susie. Good evening all and thank you for joining us on the call today. I'm pleased to note that Vertex achieved another quarter of excellent commercial results and pipeline advancement. Third quarter total revenue grew 12% year on year. Revenue growth was Thank you for watching. Before turning to the R&D update, I want to acknowledge Charlie's final and 31st earnings call as CFO. Charlie's leadership, integrity, judgment, and intellectual rigor are unparalleled. He has deftly helped lead our transition from a CF-only company with $4 billion in revenue in 2019 to a company Soon to be commercialized in five disease areas with more than triple the revenue with our guidance for over $13 billion in 2026. I look forward to continuing to work with Charlie in his role as COO, driving forward the Chronetics integration and our key priorities as we grow and scale the company. I can think of no better successor to Charlie than Jonathan Poole, our SVP and current head of finance, who will take over as CFO January 1st, 2027. Moving now to the R&D update for the quarter, I'll cover four disease areas, CF, endocrinology, both rare endocrine disorders in type 1 diabetes, and renal in detail. But first, let me start with quick highlights from four other programs. In severe sickle cell disease and transfusion-dependent beta-thalassemia, we were pleased to have recently received approval for Keshevi in patients ages 2 to 11 in the US, UAE, Bahrain, as well as in patients ages 5 to 11 in the UK. In pain, along with the strong growth in prescriptions, we're also seeing fast growth in the body of compelling Jurnavix real-world data emerge. Such as a recent paper detailing 80% or greater freedom from opioid use following total knee replacement when the pain management regimen included Jernabix. In chronic pain, both Phase III studies in painful diabetic peripheral neuropathy remain on track to complete enrollment by the end of this year and for us to be able to share results by mid-2027. In myotonic dystrophy type 1 or DM1, we remain on track to share interim results from the Galileo Global Phase 1-2 clinical trial of VX670 before the end of the year. And in generalized myasthenia gravis, we have completed enrollment of the Aetna Phase 2 dose ranging study of povitacicept and expect to share proof of concept data in the first half of 2027. Moving on to the more detailed R&D review, starting with Cystic Fibrosis. We see Oliftrec as the most effective medicine approved for CF. With once daily dosing, Oliftrec can treat up to 95% of people with CF, and in our trials, more than 75% of Allie Treated Patients ages 12 and older achieve sweat chloride levels in the range of CF carriers. That is to say, Oliftrac Treated Patients are achieving sweat chloride levels associated with no manifestation of CF disease nor reduced life expectancy. On the regulatory front, we continue our work to expand to treating younger patients and have initiated global submissions for a lift-track approval in children ages 2 to 5. Lastly in CF, an update on our next generation 3.0 correctors. We studied VX828 as part of a triple combination in a cohort of 8 people with CF and as a dual therapy in another cohort of 8. All 16 patients had FMF mutations, which is a more challenging population to treat than patients with FF mutations. In this FMF population, the VX828 dual combination did not alter sweat chloride relative to the Trikafta baseline. In the triple combination versus a baseline on Trikafta, VX828 delivered a 6.6 mmol per liter reduction in sweat chloride at day 28 and a 9.4 mmol reduction through day 28. The VX828 regimen is oral once daily with a good safety, tolerability, and DDI profile. In short, these are excellent results. However, given the very high bar set by a lift track, we intend to wait for all the data from the NextGen 3.0 family of molecules before determining next steps, namely advancement into pivotal development. VX581 and VX272, the other NextGen 3.0 correctors, are currently in first in human studies and the NextGen 4.0 molecules are in late preclinical development. Moving to our newest pillar, rare endocrinology. With the chronetics acquisition now closed, Palsonify and Acromegaly is our eighth commercialized medicine, and Duncan will provide details on the ongoing U.S. launch. On the R&D side, the most advanced molecule after Palsonify is Atrumelanant in Congenital Adrenal Hyperplasia, or CAH. which has orphan drug designation in the US, EU, and Japan, and where the Phase 3 pivotal trial is well underway. The primary efficacy endpoint for this Phase 3 study is the proportion of patients achieving the combination of normalization of androgens and physiologic glucocorticoid dose levels. This is the true goal in CAH therapy, and it is what was demonstrated in the Phase 2 trial. It is also what no other CAH medicine to date has attempted to achieve. In adult CAH, we are targeting completion of enrollment in the Phase 3 study in Q1, 2027. The study then calls for 32 weeks of dosing. In pediatric CAH, Achumel Nant is in a Phase 2 dose-ranging study. Our goal is to rapidly advance the pediatric program into pivotal development following planned regulatory interactions. In addition, the adaptive Phase 2-3 Global Study of Acumelant in ACTH-dependent Cushing Syndrome is already underway outside the U.S. and was recently granted orphan drug designation in the U.S. We have planned engagements with the FDA to confirm their expectations for this program and look forward to updating you in the coming months. Let me now turn to T1D. After careful analysis, we have chosen to prioritize acceleration of VX017 as our lead program. Recall, VX017 is an allogeneic, off-the-shelf, glucose-responsive, insulin-producing, fully differentiated islet cell therapy. It has a similar target product profile to ZamyloCell, but is designed for people with all blood types. This doubles the eligible patient population to about 120,000 people. The potential to bring transformative benefit to even more patients is the key reason to focus on VX017 given the resource intensity, complexity, and manufacturing demands of cell therapy programs. We have already begun dosing patients with VX017 in a Phase 1-2 study. Our near-term goals are to demonstrate proof of concept and to scale up manufacturing, with the goal of moving to pivotal development next year. Finally, we continue to progress our serial innovation work in T1D, focused on improved immunosuppression and on generating hypoimmune islets, with the goal of making this potentially curative therapy available To even more people. Turning now to Reno, where we have four programs in mid and late stage development. Starting with POVI and IGAN, we are both excited and ready for our Purdue for date on November 30th, just weeks away. Duncan will address our launch readiness. We just wrapped up a sparkling ASN annual meeting with the Rainier Phase 3 Interim Analysis Presentation and Publication in the New England Journal of Medicine supporting what we believe is a differentiated, potentially best-in-class profile for POVI in IGAN. Simply put, POVI will offer a trifecta of excellence in efficacy, tolerability, and patient-centric administration features. I'll focus tonight just on the patient-centric features. The commercial presentation of POVI is clearly differentiated, with a small volume, 0.46 mL, once every four weeks, subcutaneously dosed via auto-injector at home. On this point, this advantage is reflected in the poster presented by If At All at the recent ASN of a qualitative survey study of about 25 adults with IGAN in the U.S. That revealed 96% of patients preferred an autoinjector relative to injection via a pre-filled syringe and 80% preferred dosing every four weeks versus weekly. Our ambition is to launch POVI globally. To that end, we have already completed our filing for potential accelerated approval in the Kingdom of Saudi Arabia, where it has been granted breakthrough status. We estimate KSA represents an incremental 7,000 patient opportunity. And we are planning forward for our regulatory submissions in other regions, including Europe and Asia, when the study completes and the two-year EGFR data are available. On POVI in membranous nephropathy, our Olympus Phase 2-3 pivotal trial is ongoing, with Phase 3 enrollment and dosing well underway, at the selected dose of 80 mg subcutaneously every four weeks. Recall, this study has a 104-week endpoint. On Anaxipline and AMKD, we have two pieces of news since our last earnings call. First, to recap the exciting results from the amplified study. In cohort 1 of patients with AMKD and modest pertinuria, treatment with Anaxipline on top of optimized standard of care led to a 42.7% reduction in urine albumin to creatinine ratio, or UACR, at week 13 compared to baseline, with the UPCR down 44.7%. This is remarkably consistent with the treatment effect previously shared in the Phase 2 data in AMKD published in the New England Journal of Medicine. In Cohort 2, of people with AMKD and Type 2 diabetes, treatment with Anaxipline led to a 17.3% reduction in UACR and a 25.4% reduction in UPCR at Week 13. Of note, the majority of patients in both cohorts did not have a diagnosis of FSGS. Anaxipline was generally safe and well tolerated with no serious adverse events related to Anaxipline. All adverse events were mild or moderate in severity. We look forward to discussing these results with regulators in the context of the Amplitude study next year. The second key milestone was that we completed full enrollment in the pivotal Amplitude Phase 2-3 trial, and we are fully on track to share the results from the interim analysis of Amplitude early next year. If positive, this interim analysis will support potential accelerated approval in the U.S. Rounding out on renal enrollment in the VX407 Aglow Phase II study in ADPKD completed enrollment, and we are now on track for study readout next year. With that, I'll turn the call over to Duncan for a commercial update.
You're reading a preview of the VRTX Q3 2026 earnings call.
Free account.
